Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment

NCT04129775 is registered in ClinicalTrials.gov with Otonomy, Inc. as lead sponsor.

NCT NCT04129775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04129775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment
Lead sponsor
Otonomy, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 1, 2019
Completion date
September 5, 2022
Enrollment
110 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

sensorineural hearing loss